Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Pier Vitale NuzzoFilippo PederzoliCalogero SaievaElisa ZanardiGiuseppe FotiaAndrea MalgeriSabrina RossettiLoana Valenca BuenoLivia Maria Q S AndradeAnna PatrikidouRicardo Pereira MestreMikol ModestiSandro PignataGiuseppe ProcopioGiuseppe FornariniUgo De GiorgiAntonio RussoEdoardo Francininull nullPublished in: Journal of translational medicine (2023)
Our analysis suggests that the volume of disease could be a prognostic factor for patients starting AA or Enza as first-line treatment for metastatic castration-resistant prostate cancer, pending prospective clinical trial validation.